Similar to many gynecologic conditions, there is stigma and embarrassment associated with the symptoms of uterine fibroids, and seeking treatment can be difficult. This difficulty is compounded when racial and ethnic discrimination and health care disparities are taken into account. It is imperative that clinicians, both specialist and primary care, effectively utilize shared decision-making (SDM) to explore the impact of the treatments they select for patients with uterine fibroids. Plan development should focus on long-term considerations, including fertility, sexual health, disease management, financial impact, mental wellness, quality of life, racial/ethnic disparities, and mitigating risk factors/potential side effects.
In the final activity of this CME Outfitters Snack series, expert faculty will help learners to identify opportunities to integrate effective and inclusive SDM into their clinical practice and implement patient-centered treatment plans for patients with uterine fibroids.
Utilize SDM to develop patient-centered treatment plans for patients with uterine fibroids.
Supported by an educational grant from Pfizer Inc. and Sumitomo Pharma America.
Obstetrician-gynecologists, primary care physicians, nurse practitioners (NPs), physician associates (PAs), and nurses.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Al-Hendy reports the following financial relationships:
Consultant: AbbVie Inc.; Bayer; Myovant Sciences; Norvartis Pharmaceuticals Corporation; ObsEva; and Pfizer Inc.
Research Support: CrilaHealth
Ms. McKenzie reports the following financial relationships:
Consultant: Agile Therapeutics; Palatin; and Pfizer Inc.
Speakers Bureau: Astellas Pharma Inc. and Bayer.
Ms. Valbrun reports the following financial relationships:
Consultant: Myovant Sciences/Pfizer Inc.
Grants: (Paid to The White Dress Project) Ferring Pharmaceuticals; Gynesonics; Hologic, Inc.; and Myovant Sciences/Pfizer Inc.
Speakers Bureau: Myovant Sciences/Pfizer Inc.
Disclosures were obtained from the Outfitters, LLC staff; no disclosures to report:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at 877.CME.PROS (877.263.7767).